Metal-Based Drugs

Metal-Based Drugs / 2009 / Article / Tab 1

Research Article

In Vitro Evaluation of Oxoplatin: An Oral Platinum(IV) Anticancer Agent

Table 1

Selected genes exhibiting fourfold upregulated expression in H526 cells that were treated with oxoplatin assorted according to their cellular function. H526 SCLC cells were either left untreated or treated with 3.75  M oxoplatin, respectively, in tissue culture flasks for three days. Thereafter, RNA of control and treated cells was extracted, and gene expression was analyzed using the Applied Biosystems Human Genome Survey Microarray V2.0.

Cellular process Locus linkGene symbolGene name

Transcription2306FOXD2 Forkhead box D2
5450POU2AF1POU domain, class 2, associating factor 1
1649DDIT3 DNA-damage-inducible transcript 3

Apoptosis84301DDI2DNA-damage inducible protein 2
9518GDF15Growth differentiation factor 15
836CASP3Caspase 3, apoptosis-related cysteine protease
8349HIST2H2BEHistone 2, H2be

Cytoskeleton649BMP1 Bone morphogenetic protein 1
2620GAS2Growth arrest-specific 2
5414PNUTL2Peanut-like 2 (Drosophila)
5100PCDH8Protocadherin 8

Signal transduction10673TNFSF13B Tumor necrosis factor (ligand) superfamily, member 13b
10368CACNG3 Calcium channel, voltage-dependent, gamma subunit 3
8416ANXA9 Annexin A9
1184CLCN5Chloride channel 5 (nephrolithiasis 2, X-linked, Dent disease)
147798TMC4 Transmembrane channel-like 4

Metabolism50506DUOX2 Dual oxidase 2
81894SLC25A28 Solute carrier family 25, member 28
3067HDC Histidine decarboxylase
8644AKR1C3Aldo-keto reductase family 1, member C3
6569SLC34A1Solute carrier family 34 (sodium phosphate), member 1
10404PGCPPlasma glutamate carboxypeptidase
9709HERPUD1 Homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1
6303SATSpermidine/spermine N1-acetyltransferase

Transport1520CTSSCathepsin S
27074LAMP3Lysosomal-associated membrane protein 3
4189DNAJB9DnaJ (Hsp40) homolog, subfamily B, member 9

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.